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Background: Assessing the risk of bias of randomized controlled trials (RCTs) is crucial to understand how biases
affect treatment effect estimates. A number of tools have been developed to evaluate risk of bias of RCTs; however,
it is unknown how these tools compare to each other in the items included. The main objective of this study was
to describe which individual items are included in RCT quality tools used in general health and physical therapy
(PT) research, and how these items compare to those of the Cochrane Risk of Bias (RoB) tool.
Methods: We used comprehensive literature searches and a systematic approach to identify tools that evaluated
the methodological quality or risk of bias of RCTs in general health and PT research. We extracted individual items
from all quality tools. We calculated the frequency of quality items used across tools and compared them to those
in the RoB tool. Comparisons were made between general health and PT quality tools using Chi-squared tests.
Results: In addition to the RoB tool, 26 quality tools were identified, with 19 being used in general health and
seven in PT research. The total number of quality items included in general health research tools was 130,
compared with 48 items across PT tools and seven items in the RoB tool. The most frequently included items in
general health research tools (14/19, 74%) were inclusion and exclusion criteria, and appropriate statistical analysis.
In contrast, the most frequent items included in PT tools (86%, 6/7) were: baseline comparability, blinding of
investigator/assessor, and use of intention-to-treat analysis. Key items of the RoB tool (sequence generation and
allocation concealment) were included in 71% (5/7) of PT tools, and 63% (12/19) and 37% (7/19) of general health
research tools, respectively.
Conclusions: There is extensive item variation across tools that evaluate the risk of bias of RCTs in health research.
Results call for an in-depth analysis of items that should be used to assess risk of bias of RCTs. Further empirical
evidence on the use of individual items and the psychometric properties of risk of bias tools is needed.
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Randomized controlled trials (RCTs), and systematic re-
views (SRs) and meta-analyses of these trials, are consid-
ered the gold standard to evaluate the effectiveness of
health care interventions. Results of these studies are
crucial for informing the implementation of the best
treatments to improve patient outcomes and the effi-
ciency of the health care system. Evaluating the meth-
odological quality of trials is an essential component of
SRs as only the best available evidence should inform
clinical and policy decisions. An accurate assessment
of study quality is key for the synthesis and interpret-
ation of results across studies to effectively guide health
care [1].
The term “methodological quality” has evolved since
its inception and involves the evaluation of the internal
validity as well as the external validity of a given study
[2,3]. Recently, The Cochrane Collaboration has lead a
shift in the approach to quality assessment, in which the
concept of trial quality is linked to the internal validity
of the study, namely risk of bias [4]. However, there is
still inconsistency among researchers on how study qual-
ity is defined, and several terms have been used inter-
changeably in the literature (i.e. quality assessment,
methodological quality, risk of bias, critical appraisal,
trial quality).
While the impact of trial bias on evidence synthesis
has been largely recognized, the approaches to quality
assessment have been inconsistent and controversial [5].
A wide variety of tools have been developed to evaluate
RCT quality in different health areas.[5,6]; many of them
have not been developed using scientifically rigorous
methods nor have they been validated [5]. In addition,
there is no agreement on the optimal tool to accurately
assess trial quality. The use of different tools for evaluat-
ing the quality of primary research in SRs can lead to
discrepancies and skewed interpretations of SR results
[7-9] and ultimately impact recommendations for clin-
ical care.
In 2008, The Cochrane Collaboration [10] intro-
duced the Risk of Bias (RoB) tool as a way to address
shortcomings associated with existing tools and
methods for quality assessment in SRs. Individual
RoB items were selected based on a growing body of
empirical evidence quantifying the association be-
tween certain characteristics related to the conduct of
the trial and estimates of treatment effects [11-15].
For example, there is evidence that inadequate alloca-
tion concealment or lack of double-blinding are likely
to overestimate treatment effects by 18% and 9%, re-
spectively [12,14,15].
In order to guide a proper assessment of study quality
or risk of bias to inform decision-making, it is important
to identify which items have been included in differenttools and whether these items truly evaluate the likeli-
hood of bias, as defined by The Cochrane Collaboration
[10,16] and other criteria [17]. This would be an import-
ant contribution for evidence synthesis.
Most of the studies that have evaluated the use of
tools for quality assessment of RCTs [5,6,18,19] have
not exhaustively assessed how these tools compare to
each other in terms of their individual items and
whether their use varies across different areas of
health care research. For example, a recent study [19]
examined the characteristics and methods of reviews
assessing the quality of RCTs. While substantial vari-
ation in the use of quality tools across reviews was
identified, the study did not describe in detail which
items were most frequently included in the tools. The
present study was designed to refine the analysis of
existing tools by conducting a more comprehensive
search (i.e., no language restrictions, larger number of
databases), describing the psychometric properties of
the tools used in general health research, and com-
paring the items included in these tools with the
Cochrane RoB tool.
We conducted a previous systematic review that de-
scribed which tools have been used to evaluate the
methodological quality of RCTs in physical therapy
(PT) research [5]. RCTs conducted in the area of PT
have unique characteristics compared with pharmaco-
logical trials. Because of the nature of PT treatments
(e.g., manual therapy, exercises), RCTs assessing PT
interventions are often complex [20], and diverse as-
pects of their design (e.g., type and intensity of ther-
apy, standardized or individually tailored approaches,
therapists’ skills and experience) are likely to affect
study results. It is unknown whether the tools to as-
sess the quality of RCTs in PT differ from those used
in general health research in terms of the items and
type of bias they aim to address. The present study
was designed to expand and update the analysis of
our previous review [5] on quality tools for evidence
synthesis.
The main objective of the present study was to de-
scribe the frequency of individual items included in tools
that assess RCT quality in general health and PT re-
search, and how they compare to items included in the
RoB tool [4]. Secondary objectives were to 1) determine
the nature of items included in general health and PT
quality tools (i.e., evaluation of “conduct” versus
“reporting”); 2) report on the psychometric properties of
quality tools that have been formally evaluated; 3) deter-
mine whether individual items in the tools relate to cer-
tain threats to validity or precision [10,16,17] and 4)
quantify the number of citations per tool, as a measure
of usage since each tool’s inception and after inception
of the RoB tool.
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Design: observational, descriptive study
Search strategy
An update of a previous SR [5] on quality assessment
tools was carried out to identify scales and their items
used in the assessment of RCT quality in health and PT
research. The updated search strategy incorporated key
words identified by Dechartres et al. [19], with searches
conducted from January 1st, 2007 to June 10, 2013 in
the following bibliographic databases: Medline, Embase,
Cinahl, ISI Web of Science, EMB Reviews-Cochrane
Central Register of Controlled Trials and Cochrane
Library and Best Evidence, All EBM Reviews -CDSR,
ACP journal Club, DARE, CCTR, Global health, and
HealthSTAR. Key words used in the search were: tool,
critical appraisal, critical appraisal review, appraisal of
methodology, appraisal of research methodology, re-
search design review, quality assessment, methodological
quality tool, RoB (tool), randomized (randomised)
controlled trial, and RCT. Additionally, we manually
searched the bibliographies of potentially relevant pa-
pers. The search was not limited by language of publica-
tion. For a sample search strategy, see Additional file 1.
Criteria for inclusion of studies in the review
Studies were included if they described or used a newly
developed tool to evaluate the methodological quality/
RoB of RCTs in any area of medical/health research and
described any of its psychometric properties (i.e. validity,
reliability, responsiveness). We excluded studies in which
quality tools were developed for only one specific SR,
studies that were not related to the development or psy-
chometric testing of quality tools, and studies on generic
tools that evaluated different types of research design
(e.g., qualitative and quantitative studies). In addition,
studies using modifications of existing tools were not
considered for inclusion as they were likely not system-
atically developed. The RoB tool [4,10] was known to be
newly developed after our previous SR (2008), and was
included prior to the updated search; however, we
searched for manuscripts reporting psychometric prop-
erties of the RoB tool.
Data screening
Two reviewers independently screened abstracts and
titles obtained from the database searches. The full text
of potentially relevant articles was retrieved for further
assessment. Disagreements were resolved by consensus.
Data extraction
Data extraction was conducted in two phases. First, two
researchers independently extracted information on
content, construction, special features (e.g. area of
development-clinical area-, number of items, selection ofitems for inclusion, time to complete, scoring instruc-
tions), and psychometric properties of the new tools.
Information on face, content, construct, and concurrent
validity, internal consistency, and reproducibility (intra
and inter-rater reliability/agreement) was extracted. For
this update, authors of original studies were not
contacted to obtain additional information. The defini-
tions of psychometric properties from Streiner and
Norman [21-23] were used in the present study. Guide-
lines developed by Terwee et al. [24] were used to define
quality of measurement properties. Briefly, quality of
measurement included internal (internal consistency,
relevance of items and representativeness of items of the
scale-content validity) as well as external components of
validity (the relationship with other tests in a manner
that is consistent with theoretically derived hypotheses-
construct validity). Intra and inter-rater reliability (i.e.
repeatability of measurements taken by the same tester
at different times and repeatability of measurements
taken by different testers, respectively) were also consid-
ered. Definitions of psychometric properties for this
review are provided in Additional file 2.
Second, two researchers independently extracted infor-
mation on individual items used in the tools and the fre-
quency of items across tools. Tools were categorized as
relevant to PT if the authors specifically stated that the
scale was developed for PT research, it was developed by
a PT group, or if, according to Scopus searches, the tool
was used in at least 5 PT reviews. Otherwise the tool
was considered a general health research tool. One of
the tools commonly used in both general health and PT
research is the Jadad scale. This tool was included in
both categories.
Items from the quality tools were grouped according
to nine content categories that have been previously
described [5]: 1) introduction, objectives, and design;
2) patient selection (inclusion and exclusion criteria,
description of study participants); 3) assignment, ran-
domization, and allocation concealment; 4) blinding;
5) interventions; 6) attrition, follow up and protocol
deviations; 7) outcomes; 8) statistical analysis; and
9) miscellaneous.
Classification of items
Methodological quality (conduct) and quality of repor-
ting are two concepts that overlap to some degree; how-
ever, they relate to different aspects of study quality. We
defined methodological quality as “the confidence that
the trial design, conduct, and analysis has minimized or
avoided biases in its treatment comparisons” [6] (e.g.,
allocation concealment was appropriate). We defined
quality of reporting as authors providing “information
about the design, conduct and analysis of the trial,” [6]
(e.g., method for concealing allocation was reported).
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items based on whether they evaluated “reporting” and/
or “conduct” of the trial.
Classifying quality items is a complex task due to un-
clear description of items in the tools, lack of general
agreement in bias definitions [25], and the need for em-
pirical evidence linking these items to bias. Two re-
searchers independently classified each item according
to whether they potentially addressed threats to validity
(i.e., selection bias, detection bias, performance bias, at-
trition bias) or precision (Additional file 3). These cate-
gorizations have been used in other relevant sentinel
work [17,26-28]. Items that dealt with several threats to
validity were classified as addressing multiple biases [29].
Reviewers considered each item by asking “What type of
threats to validity or precision are addressed by a given
item?” or “What do authors intend to capture with a
given quality assessment item?” Thus, items were classi-
fied into the threats to validity or precision that best repre-
sented the concepts being addressed. We performed this
task in duplicate and based on the guidelines established.
The same type of analysis has been conducted previously
for prognosis research [28]. Disagreements in item classifi-
cation were resolved by consensus.Tool citation
Each quality tool was tracked in the Scopus database to
determine the number of times that the tool was cited
since its original paper/citation. The number of citations
per tool was tracked from January 1, 2007 to July 4,
2013 to describe recent uses of the tool and to ascertain
whether the use of the tool declined after introduction
of the RoB tool. The RoB tool was originally described
in Chapter 8 of the Cochrane Handbook [10]. Since
books and book chapters are not indexed in electronic
databases, it was more challenging to track citations for
the RoB tool. We tracked RoB citations using Google
Scholar and the journal publication by Higgins et al. [4],
that reported on the RoB tool.Analysis
Data were summarized descriptively as the frequency of
each item across quality tools, and within general health
and PT research. Comparisons of items from PT and
general health research tools with the RoB tool were also
conducted. Comparisons between the proportion of in-
dividual items used by PT tools and general health re-
search tools were performed using Chi-squared or
Fisher exact tests. The alpha level was set at α = 0.05.
The level of agreement between reviewers for study
selection and data extraction from quality tools was cal-
culated using percentage agreement and the Kappa (κ)
statistic [30]. Analyses were performed using StataStatistical Software: Version 12, 2012 (College Station,
TX: StataCorp LP).
Results
The updated electronic searches identified 32,627 cita-
tions. Manual searches identified four additional studies
based on their titles and abstracts. After screening titles
and abstracts, 154 articles were deemed potentially rele-
vant. The application of the selection criteria resulted in
148 excluded studies. The main reasons for exclusion of
studies were: 1) the study used a quality tool for which
information on construction, development and/or psy-
chometric properties was not available (n = 40); 2) the
tool was already included in the original review (n = 39);
3) the study used a tool that was not specific for RCT
quality assessment (n = 23); 4) the study used a modified
tool already included in the review (n = 20); 5) the study
used an instrument that was not a quality tool (n = 11);
6) the study used a tool developed for the purposes of a
single review (n = 8); 7) the study focused on animal re-
search (n = 4); 8) the study did not focus on a particular
tool (n = 2); and 9) information on the name of the tool
was not provided (n = 1). A list of excluded studies and
reasons for exclusion is available in Additional file 4.
The level of agreement for study selection between
reviewers was excellent (kappa = 0.96).
Six manuscripts [31-36] reporting on four newly devel-
oped tools met the eligibility criteria (Figure 1). These
four new tools that evaluated the methodological qual-
ity/RoB of RCTs in health research in addition to the
RoB tool [4,10] were: the Cochrane Collaboration De-
pression, Anxiety, And Neurosis (CCDAN) tool [34,35],
the Randomized Controlled Trial Psychotherapy Quality
Rating Scale (RCT-PQRS Tool) [32,33], 3) the Random-
ized Controlled Trial -Natural Products Tool (RCT-NP)
[31], and the CLEAR NPT (a checklist to evaluate the
report of nonpharmacological trials) [36]. New PT-
specific tools were not identified. The five tools were
added to the 21 tools identified in our previous review
[2] (i.e. Jadad [37], Maastricht [38], Delphi [39], PeDro
[40,41], Maastricht-Amsterdam [42], Van Tulder [43],
Bizzini [44], Chalmers [45], Reisch [46], Andrew [47],
Imperiale [48], Detsky [49], Cho and Bero [50], Balas
[51], Sindhu [52], Downs and Black [53], Nguyen [54],
Oxford Pain Validity Scale (OPVS) [55], Arrive [56],
CONSORT [57], and Yates [58]). Therefore, this update
includes 26 quality tools. Details on the characteristics
and psychometric properties of the new quality tools are
presented in Tables 1 and 2.
Most of the new tools have been tested for face and
content validity (Table 2 and Additional file 5). Evalua-
tions of other types of validity, such as criterion validity,
have been conducted only for the RCT-NP and the
RoB tool; however, the criterion used was a non-gold
Articles selected for full evaluation for 
inclusion in the review
N = 154
Reasons for exclusions
No info on construction, development and/or 
psychometric properties=40
-Tool included in original review=39
-Tool not specific for RCT assessment=23
-Modified existing tool= 20
-Not a quality assessment tool=11
-Tool developed for single review 
purposes=8
- Animal research= 4
-No focus on a particular tool=2
-Name of scale not reported=1
Duplicates removed = 5825
References selected for further examination 
of titles and abstracts
N = 32,627
Tools identified in 
previous SR
- N = 21
- PT = 7
- General = 14
New tools from 
update
N = 5
Excluded
N = 148
Total number of references identified from 
the updated electronic searches = 38,452
Included studies
N = 6
Manual literature searches = 4
Total number of 
tools analyzed
N = 26
Figure 1 PRISMA flow diagram for identification of studies.
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standard to evaluate the risk of bias or quality of RCTs in
health research). Tool reproducibility has been evaluated
for the CCDAN tool, the RCT-PQRS, and the RoB tool.
The inter-rater reliability of the RoB tool was fair (k = 0.41-
0.60) in contrast to the CCDAN and RCT-PQRS tools
which showed good inter-rater reliability (r = 0.75-0.86;
intra class correlation coefficient [ICC] =0.76-0.79).
Items from all 26 tools were summarized according to
their frequency of use. The level of agreement between
reviewers for item categorization in both PT (kappa =
0.92) and general health research tools (kappa = 0.98)
was very good to excellent.
Tools to measure methodological quality/risk of bias
Of the 26 tools, 19 have been used in general health re-
search and seven in PT research (including the Jadad
scale, which is commonly used in both research areas).
A total of 130 items have been used across general heath
research tools compared with 48 items used in PT tools.
The RoB tool has 6 domains with 7 items in total.
Additional files 5 and 6 provide a detailed description of
individual items contained in the tools. The numbers ofquality items according to the nine content categories
for general health versus PT tools were: introduction,
objectives, and design: 8 versus 0 items; patient selec-
tion: 18 versus 4 items; assignment, randomization,
and allocation concealment: 8 versus 5 items; blinding:
12 versus 10 items; interventions: 17 versus 8 items; attri-
tion, follow up and protocol deviation: 10 versus 9 items;
outcomes: 15 versus 7 items; statistical analysis: 31 versus
5 items, and miscellaneous: 11 versus 0 items.
Frequency of items: General health research tools,
physical therapy tools and RoB tool
Items addressing inclusion and exclusion criteria and the
appropriateness of statistical analysis were the most fre-
quently used among the general health research tools
(74%, 14/19 tools). The second most commonly used
items in general health research tools were description
of withdrawals and drop outs, description and appropri-
ateness of randomization process, blinding of investiga-
tors/assessors, and description of treatment protocol for
both intervention and control groups (63%, 12/19 tools).
In contrast, baseline comparability, blinding of investi-
gator/assessor, and use of intention-to-treat analysis
Table 1 Characteristics of tools identified in the search update
Study (authors, year) Area Numbers of items How items were selected
for inclusion
Validity Reliability Time to
complete
Guidelines
for use
available
NEW TOOLS (2007-2013)
COCHRANE COLLABORATION
DEPRESSION, ANXIETY, AND
NEUROSIS (CCDAN) [34,35]
Trials of
depression,
anxiety and
neurosis.
Psychological
and
Psychiatric
trials
23 items This tool was developed from
items included in other
health tools (especially
CONSORT statement), and
then a consensus from
experts was performed to
determine a pilot tool to be
tested.
Face, content and construct
validity
Reliability evaluated through
correlation coefficient among
3 raters in total score was
high. It ranged from r=0.75-
0.86.
15-20
minutes
No
Scores from raters correlated
highly with year of
publication (r=0.37-0.6)
Reliability for individual items
was less strong
Further validation consisted
on determine reliability of
the tool as well as internal
consistency and its
correlation with overall score
and year of publication.
The mean kappa for all 23
items ranged between 0.51
to 0.54 among 3 raters
Internal consistency
measured through Cronbach
alpha ranged between 0.65
to 0.78
THE RANDOMIZED
CONTROLLED TRIAL
PSYCHOTHERAPY QUALITY
RATING SCALE (RCT-PQRS
TOOL) [32,33]
Psychotherapy 25 items organized in 6
domains: Description of
subject (4 items), definition
and delivery of treatment (5
items), outcome measures (5
items), data analysis (5 items),
treatment assignment (3
items), overall quality of
study (3 items)
Items were generated by an
informal expert consensus
(members of the American
Psychiatric Committee on
Research on Psychiatric
treatments, outside
consultants, who were senior
psychotherapy and/or
psychopharmacology clinical
researchers.
The Cronbach α for all 25
items as rated by the primary
rater was 0.87.
The ICC for interrater
reliability of item 25, the
omnibus rating of the quality
of the study, was 0.79.
10-15
minutes
Yes
The correlation between the
24-item total and the
omnibus item (item 25) was
0.88.
The ICC for interrater
reliability of the total of the
first 24 items was 0.76.
The correlation between the
24-item total and study year
was 0.51, significant at P <
.0001.
Nine of the individual items
had individual ICCs between
0.5 and 0.8 (items 2, 4, 6, 7, 8,
10, 14, 15, and 19).
The correlation of the
omnibus item and study year
was 0.47 (P < .0001).
Twelve items had individual
ICCs between 0.3 and 0.5
(items 1, 3, 5, 9, 11, 12, 13, 16,
17, 18, 20, and 24), and 3 items
had individual ICCs below 0.3
(items 21, 22, and 23).
Two items had very low
variation between studies (77%
of studies received a 0 on item
13 and 97% of studies
received a 2 on item 21).
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Table 1 Characteristics of tools identified in the search update (Continued)
THE RCT-NATURAL PRODUCTS
TOOL (RCT-NP) [31]
Trials of
Natural
products
28 items The initial list of items for this
study was compiled from
items contained in published
critical appraisal instruments
designed for RCTs of NPs as
well as from items suggested
by the research team.
Comparisons with a
published instrument to
evaluate the methodological
quality of RCTs for Natural
product was used (criterion
validity). Similar results were
obtained with both
instruments indicating
criterion validity (Concurrent
validity)
N reported Not
reported
Yes
A Delphi process was used to
achieve consensus among a
group of experts as to which
items describing the identity
of an NP were essential to
consider when critically
appraising an RCT of an NP.
Raters’ answers were
compared with investigators
answers to determine
criterion validity as well. No
significant differences
between raters and
investigators (gold standard)
answers were obtained
The consensus building
process was conducted in 2
rounds using email.
Consensus was considered to
have been reached when
80% of participants were in
agreement with an item
being designated as essential
to include in the instrument
A final list of items
considered to be essential by
the study participants and
investigators was assembled.
A systematic review
regarding tools used in to
evaluate quality of NPs trials
was performed. Items from
all of these tools were
compiled
To be designated as essential
to include in the new critical
appraisal instrument, an item
had to meet at least 1 of the
following 2 inclusion criteria:
it had to have been
contained in a published
instrument that was
documented as having been
validated or must have had
empirical evidence to
support its inclusion in a
published instrument.
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Table 1 Characteristics of tools identified in the search update (Continued)
A CHECKLIST TO EVALUATE A
REPORT OF A
NONPHARMACOLOGICAL
TRIAL (CLEAR NPT) [51]
Health
Research
10 items and 5 subitems Initial pool of items was
performed from existing
quality tools identified by
Moher et al. and Verhagen
and the CONSORT statement,
users’ guides to the medical
literature, and the Cochrane
Reviewers’ Handbook.
Content validity was
provided by experts in the
field through the Delphi
method
Not reported 10
minutes
Yes
Items specific to NPT trials
identified in a preliminary
study and during informal
interviews of clinicians
working in the field of NPT
were added.
Thirty-eight potential items
were identified.
A Delphi procedure was used
to determine the final items
included in the tool.
RISK OF BIAS TOOL (RoB)
[4,10]
Health
Research
The risk of bias tool is based
on six domains and 7 items:
sequence generation,
allocation concealment,
blinding, incomplete
outcome data, selective
outcome reporting, and
“other sources of bias.”
Critical assessments on the
risk of bias (high, low,
unclear) are made separately
for each domain.
The choice of components
for inclusion in the tool was
based on empirical evidence
showing their association
with effect estimates.
Content validity: items were
included based on empirical
evidence.
Interrater agreement for the
individual domains of the
risk of bias tool ranged from
slight (κ=0.13 for selective
reporting) to substantial
(κ=0.74 for sequence
generation [13].
~21
minutes
Yes
Concurrent validity: A high
degree of correlation was
found between the domains
of risk of bias sequence
generation compared with
Jadad randomisation (k=0.79)
and risk of bias allocation
concealment compared with
Schulz allocation
concealment (k=0.73) [13]
The RoB demonstrated
moderate to substantial
(mean values 0.56 to 0.76)
agreement on three of
twelve items [59].
The interrater agreement
was fair (0.40) for selective
outcome reporting and
almost perfect (0.86) for
sequence generation [62].
Correlation was low for the
comparisons between the
domains of risk of bias
incomplete outcome data
and the Jadad withdrawal
item, risk of bias overall risk
and total Jadad score, and
risk of bias overall risk and
Schulz allocation
concealment [13]
Interrater agreement for the
majority of domains and
overall risk of bias was
moderate (k = 0.41–0.60)
[60].
The correlations between
overall risk of bias
assessments and total Jadad
score (t= 0.04) and allocation
concealment (t = 0.02) were
low [60].
The inter-rater reliability
across individual domains of
the CCRBT was found to be
0.30, which is considered
slight agreement between
raters [46]. The inter-rater
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Table 1 Characteristics of tools identified in the search update (Continued)
reliability of the final grade
assigned to each paper by
this tool was ICC = 0.58 (95%
CI 0.20–0.81)[61]
There was very poor
agreement between the
Effective Public Health
Practice Project Quality
Assessment Tool (EPHPP)
and the RoB tool in the final
grade assigned to each
study (kappa = 0.006)[61]
The inter-rater reliability was
substantial for sequence
generation (k=0.79) and fair
for the other 5 items (k=0.24-
0.37). Interrater reliability
between consensus
evaluations across rater pairs
was fair for allocation
concealment and “other
sources of bias” (k=0.37-0.27),
and moderate for sequence
generation (k=0.60). [62]
95% CI = 95% confidence interval, CONSORT Consolidated Standards of Reporting of Trials, ICC intraclass correlation coefficient, k kappa, NP natural products, NPT natural products trials, RCT randomized controlled trial,
RoB risk of bias.
A
rm
ijo-O
livo
et
al.BM
C
M
edicalResearch
M
ethodology
2013,13:116
Page
9
of
19
http://w
w
w
.biom
edcentral.com
/1471-2288/13/116
Table 2 Summary of the quality of measurement properties of quality tools from our previous systematic review and
this update
Scale Internal
consistency
Face
validity
Content
validity
Criterion
Validity*
Construct
validity
Reproducibility
(agreement/reliability)
TOOLS FOR PT
Jadad Tool [37] - + + + + +
Maastricht Tool [38] - + - + - +
Delphi Tool [39] - + + + - +
PEDro Tool [40,41] - + + - - +
Maastricht-Amsterdam Tool [42] - + + - - +
Van Tulder Tool [43] - + + + - +
Bizzini tool [44] - + + - - +
TOOLS FOR GENERAL HEALTH RESEARCH
Tools from previous systematic review
Chalmers tool [45] - + + + - +
Reisch Tool [46] - + - + - -
Andrew tool [47] - + - - - +
Imperiale tool [48] - + - + - -
Detsky tool [49] - + - + - +
Cho Tool [50] - + - + - +
Balas tool [51] - + - - - -
Sindhu tool [52] - + + + - +
Downs and Black tool [53] + + + + - +
Nguyen tool [54] - + - - - -
Oxford pain validity tool [55] - + - - - -
Arrive tool [56] - + - - - +
CONSORT tool [57] - + + - - +
Yates Tool [58] - + + - + +
New tools identified in search update
Cochrane Collaboration Depression, Anxiety, and
Neurosis (CCDAN) [34,35]
+ + + - + +
The Randomized Controlled Trial Psychotherapy Quality
Rating Tool (RCT-PQRS Tool) [32,33]
+ + + - + +
RCT-Natural Products Tool (RCT-NP) [31] - + + + - -
CLEAR NPT (Checklist to evaluate a report of a
nonpharmacological trial [36]
- + + - - -
Risk of Bias Tool (RoB) [4,10] - + + + + +
+Quality of measurements properties were based on guidelines established by Terwee et al. [13].
(+): criterion accomplished.
(−): Criterion not accomplished.
* In all cases, criterion validity was established with “no gold standard tools”.
PT physical therapy, RCT randomized controlled trial.\
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http://www.biomedcentral.com/1471-2288/13/116were the most frequently used items among PT tools
(86%, 6/7) (Additional files 5 and 6, Figures 2 and 3).
The second most frequently used items in PT tools
were: reporting of withdrawals and dropouts, method of
randomization concealment, description of inclusion/ex-
clusion, reporting of descriptive measures for point esti-
mates, blinding of therapist, and blinding of participants
(71%, 5/7 tools) (Figures 2 and 3).Inclusion of the following items was significantly more
frequent in PT tools compared with general health re-
search tools: “intention to treat” (p = 0.014), “withdraws
and drop outs acceptable” (p < 0.001), and “baseline
comparability” (p = 0.027).
When RoB items were individually examined, we
found that sequence generation and allocation conceal-
ment were included in 5 of the 7 PT tools (Figure 4).
73.7
73.7
63.2
63.2
63.2
63.2
57.9
52.3
52.3
52.3
47.4
47.4
42.1
42.1
42.1
36.8
36.8
36.8
31.6
31.6
31.6
31.6
31.6
0 10 20 30 40 50 60 70 80
Inclusion and exclusion criteria clearly defined
Appropriate statistical analysis
Description of withdrawals and Drop outs
Description of randomization process reported and appropiate
Blinding of investigator/assessor
Treatment protocol adequately described for the treatment and control groups
Study described as randomized
Study question/hypothesis described and well defined
Description of sample characteristics
Description of outcome measures/criteria for measuring outcomes
Blinding of subjects
Sample size calculation performed prior to initiation of the study
Type of Statistical test used clearly stated
Power calculation
Testing of subject compliance to treatment protocol
Baseline comparability
Allocation concealment
Blinding of therapist
Clear reporting of number of subjects excluded from the trial
Reliability reported for main outcome measures
p value and/or confidence intervals reported
Study conclusion supported by the findings of the study 
Intention to treat
%
Figure 2 Frequency of items used by tools used in general health research to measure methodological quality RCTs. RCT = randomized
controlled trial.
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http://www.biomedcentral.com/1471-2288/13/116Only four PT tools evaluated whether randomization
was performed. Twelve (63%) general health research
tools included randomization whereas seven (37%) in-
cluded an item for allocation concealment. Further,
fewer of the general health research tools included items
related to blinding compared with the PT tools: blinding
of participants (47% versus 71%) and blinding of out-
come assessors (63% versus 86%). Intention to treat ana-
lysis, a component of the incomplete outcome data
domain in the RoB tool was more frequently used in PT
tools (86%) compared with general health research tools
(32%). Other items related to incomplete outcome data
in the RoB tool are “description of withdrawals and drop
outs” and “appropriateness of withdrawal/drop outs
rate”. Compared with the general health research tools
(63%), a larger proportion of PT tools (71%) included
items for the description of withdrawals and drop outs.
In contrast, none of the general health research tools in-
cluded an item about whether the withdrawal/drop-out
rate was acceptable compared with 57% of the PT tools.
Another quality item used in the RoB tool is baseline
comparability. This item was included in 86% of PT
tools compared with 37% of the general health research
tools. In general, PT tools appeared more similar in con-
tent to the RoB tool than those used for general health
research (Figure 4).Reporting versus conduct items and threats to validity
and precision
Of the 130 items included in the general health research
tools, 62 (48%) evaluated trial “reporting” whereas 60
items (46%) evaluated “conduct” (i.e. methodological
quality or risk of bias). Eight items (6%) were considered
to evaluate both quality of reporting and conduct of tri-
als (i.e. sample representativeness and description of par-
ticipants source, description of randomization process
reported and appropriate; testing of subject compliance
to treatment protocol /report of compliance; therapist
training and level of experience in the treatment(s)
under investigation; validity, reliability and responsive-
ness of the outcome measures reported; post-hoc power
calculations and confidence intervals reported).
Classification of items from general health research
tools according to type of bias and threats to precision
was as follows: selection bias (25 items, 19%); perform-
ance bias (six items, 4.6%); performance and detection
bias (six items, 4.6%); performance bias and contamin-
ation (seven items, 5.4%); performance bias and compli-
ance (two items, 1.6%); attrition bias (ten items, 7.8%);
information bias (six items, 4.6%); detection bias (five
items, 3.8%); reporting bias (17 items, 13%); threats to
precision (four items, 3.1%); statistical bias (three items,
2.3%); threats to precision and statistical bias (two items,
85.7
85.7
85.7
71.4
71.4
71.4
71.4
71.4
71.4
71.4
57.14
57.14
57.1
42.9
42.9
42.9
42.9
42.85
28.6
28.6
28.6
28.6
28.6
28.6
14.3
0 10 20 30 40 50 60 70 80 90
Intention to treat analysis 
Blinding Investigator/assessor
Baseline comparability
Report of Withdraws and dropouts
Method of randomization concealed
Inclusion/exclusion criteria defined
Descriptive measures for point estimates
Blinding Therapist
Blinding participants
Method of randomization appropriate
Withdraws and dropouts rate acceptable
Co-interventions avoided or comparable
Randomization method performed
Study described as randomized
Treatment protocol described for treatment group
Appropiate statistical analysis used
Method of randomization described
Reasons for withdrawal and drop outs
The timing of outcome measure was comparable
Relevant outcomes included
Adverse effects described
adherence/compliance acceptable in all groups
Adequate sample size
Treatment protocol described for control group
Study described as double blinded
%
Figure 3 Frequency of items used from tools used in PT research to measure methodological quality of RCTs. PT = physical therapy;
RCT = randomized controlled trial. Results expressed as percentages.
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http://www.biomedcentral.com/1471-2288/13/1161.6%); multiple biases (three items, 2.3%); and other (i.e.,
not classified as related to threats to validity or preci-
sion) (27 items, 21%) (Additional file 5).
Of the 48 items included in PT tools, 16 (33.3%) evalu-
ated trial “reporting” whereas 28 (58.3%) evaluated “con-
duct”. Four items (8.3%) were considered to evaluate
both quality of trial reporting and conduct: testing/re-
port subject compliance to treatment protocol, and
validity, reliability and responsiveness of the outcome
measures reported.
The classification of items from PT tools according to
type of bias and threats to precision was as follows: se-
lection bias (10 items, 21%); performance and detection
bias (five items, 10%); performance bias only (six items,
135%); performance and contamination bias (two items,
4.2%); performance and compliance bias (two items,
4.2%); information bias (five items, 10%); attrition bias
(eight items, 17%); detection bias (three items, 6.3%);
reporting bias (three items, 6.3%); threats to precision
(two items, 4.2%); and statistical bias (1 item, 2.1%).
(Additional file 6).
Frequency of citations of quality tools
The number of citations per quality tool since its incep-
tion and after 2007 are detailed in Table 3. The Jadadscale was, by far, the most cited and used tool with 5,326
citations from inception (i.e., year 1996) to July 4, 2013.
The second most cited tool was the Downs and Black
tool, with 962 citations since its introduction in 1998.
Other tools frequently cited were: PeDro, Delphi, and
Chalmers tools (651, 625, and 584 citations from in-
ception, respectively), followed closely by the Van
Tulder (560 citations) and Maastricht-Amsterdam
(360 citations) tools. Among the most frequently cited
tools, a larger proportion (5/7) were PT tools com-
pared with only two of the 19 general health research
tools (i.e. Jadad and Chalmers). The relative number
of citations for the tools after 2008 was similar to
those of previous years. Particularly, the use of the
Jadad tool (i.e. number of citations from 2007 to July
4, 2013: 3,672) did not show a decrease (in terms of
absolute numbers of citations) after the inception of
the RoB tool in 2008 (Table 3). Tracking of the RoB
tool showed that it has been cited approximately
1230 times since inception. This number is likely an
underestimate because of the challenges described
above with respect to tracking the Cochrane Hand-
book chapter that first described the tool. However,
this information provides a reference point to track
usage of the RoB tool over time.
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Figure 4 Comparison between RoB tool domains and items from PT and health sciences tools. PT = physical therapy; RoB = risk of bias.
Results expressed as percentages.
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This study examined tools and individual items used in
general health and PT research to assess the quality of
RCTs. A variety of tools are still widely used despite crit-
icisms raised regarding their limitations [8,63]. This find-
ing is consistent with previous reviews on this topic that
have identified inconsistencies in the use of quality tools
[5,6,18]. There is extensive variation in individual items
included across quality assessment tools. Many of these
items may not be indicators of bias nor related to over-
or under-estimations of treatment effects. Moreover,
there is lack of empirical evidence supporting the associ-
ation of many individual quality items with changes in
the magnitude and direction of treatment effects. This
finding raises important concerns in the field of quality
assessment regarding the appropriateness of evaluating
the evidence based on the use of these tools and items.
Results of this study agree with those of Deschartres
et al. [19] which found that a large number of tools have
been used in reviews that assessed the quality and
reporting of RCTs. According to Deschartres et al. [19],
ambiguity and lack of a unique definition of trial “qual-
ity” accounts for the heterogeneity of quality assessmenttools. According to Verhagen et al. [2], methodological
quality assessment involves the evaluation of internal
validity (the degree to which the study design, conduct
and analysis have minimized biases), external validity
(the extent to which study results are generalizable be-
yond the experimental situation), and statistical analysis
of primary research. According to The Cochrane Collab-
oration [10], internal validity of a trial is linked to “risk
of bias” and it should be the primary focus of quality as-
sessment since external validity differs upon context. In
addition, “quality of reporting” is commonly used as a
proxy for trial quality, which has complicated the
construct of “quality” even more.
A clear and consistent definition of “quality” across
health research areas is necessary to advance the field of
quality assessment. Furthermore, concepts such as
internal validity, external validity, and quality of
reporting should be explicitly and clearly defined for
the constructs that the individual items are meant to
address. Finally, items assessing the methodological
quality (or internal validity) of RCTs should be based
on empirical evidence of their association with treat-
ment effects.
Table 3 Frequency of citations of Quality Tools in Scopus Database
Tool All years until
July 4, 2013
From January 2007-
July 4, 2013
Year 2007
before RoB
tool
Year
2008
Year
2009
Year
2010
Year
2011
Yea
201
Year 2013 Until
July 4, 2013
Subject area most used
PT TOOLS
Jadad [37] 5326 3672 393 468 616 514 634 706 341 Medicine
Maastricht [38] 106 45 3 6 10 5 7 9 5 Medicine/health professions
Delphi [39] 625 454 39 65 71 77 87 75 40 Medicine/health professions
PEDro [40,41] 651 555 49 52 87 91 101 108 67 Health professions/ Medicine
Maastricht-Amsterdam [42] 360 158 34 36 23 21 21 19 4 Medicine/health professions
Van Tulder [43] 560 482 43 58 101 86 65 93 34 Medicine/health professions
Bizzini [44] 65 50 4 15 7 6 9 4 5 Medicine/health professions
GENERAL HEALTH RESEARCH TOOLS
Tools From Previous Systematic Review
Chalmers [45] 584 151 19 21 29 19 19 29 15 Medicine/Psychology
Reisch [46] 56 26 2 4 5 2 8 4 1 Medicine/ Nursing
Andrew [47] 10 0 0 0 0 0 0 0 0 Medicine
Imperiale [48] 141 47 6 7 8 4 8 10 4 Medicine/ Pharmacology,
Toxicology and Pharmaceutics
Detsky [49] 281 120 15 20 21 14 17 20 13 Medicine/ Biochemistry/
Nursing
Cho [50] 109 30 4 4 5 3 5 5 4 Medicine/ Pharmacology,
Toxicology and Pharmaceutics
Balas [51] 37 5 0 3 1 0 0 0 1 Medicine
Sindhu [52] 31 11 2 2 3 1 3 0 0 Medicine/Nursing
Downs and Black [53] 962 783 80 72 100 125 146 163 97 Medicine/Nursing
Nguyen [54] 84 63 6 9 9 9 14 11 5 Dentistry/Medicine
Oxford pain validity tool [55] 143 49 11 14 7 10 2 3 2 Medicine/Neuroscience
Arrive [56] 23 6 2 2 2 0 0 0 0 Medicine
CONSORT [57] 184 124 30 21 20 14 14 17 8 Medicine/Biochemistry
Yates [58] 35 33 2 1 4 7 8 6 5 Medicine/Neuroscience
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Table 3 Frequency of citations of Quality Tools in Scopus Database (Continued)
NEW TOOLS
Cochrane Collaboration Depression,
Anxiety, and Neurosis (CCDAN) [34,35]
59 44 3 6 11 6 10 7 1 Medicine/psychology
The Randomized Controlled Trial
Psychotherapy Quality Rating (RCT-PQRS)
[32,33]
30 30 0 0 0 0 10 16 4 Medicine/psychology
RCT-Natural Products (RCT-NP) [31] 3 3 0 0 1 1 1 0 0 Pharmacology, Toxicology
and Pharmaceutics
CLEAR NPT (Checklist to evaluate a report of
a nonpharmacological trial [36]
108 102 16 18 17 10 17 16 8 Medicine
Risk of Bias (Scopus Track) Higgins et al.,
2011 [4]
124 1 41 75 Medicine
Risk of Bias(Google Scholar) Chapter 8:
Cochrane Handbook (2008-July4, 2013) [10]
1155 1155 Medicine
Total RoB 1230*
*This number could include duplicates; RoB risk of bias.
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http://www.biomedcentral.com/1471-2288/13/116The number of items across quality tools is large; 130
and 48 items have been used by tools in general health
and PT research, respectively. Some items are subjective,
confusing, and lack a clear definition (e.g., subjects ap-
propriate to study questions, discussion of bias resulting
from non-blinding assessment). These factors make the
evaluation of individual items challenging and likely con-
tribute to low inter-rater agreement. Many quality items
relate to “reporting” rather than “conduct” of trials; ap-
proximately half of the items from these tools relate to
reporting only. This finding is consistent with results de-
scribed by Deschartres et al. [19], in which 25% of meth-
odological reviews stated that RCTs reported details of
sample size calculation, but only 6% reported on ad-
equacy of the sample size. Although clear reporting is
necessary to assess the quality of trial conduct, a focus
on quality of reporting can hide differences in trial con-
duct and lead to under- or over-estimation of the meth-
odological quality [64].
Comparison of items between PT and general health
research tools with RoB tool
We found that items frequently included in the PT tools
were more closely linked to items/domains included in
the RoB tool than those of general health research tools.
This result suggests that PT tools are more closely
linked to an examination of bias than the general health
research tools.
Empirical evidence has supported many items in the
RoB tool. There is a substantial interest in investigating
which methodological features of RCTs are associated
with treatment effects. Evidence informing this associ-
ation comes mainly from RCTs in the area of medicine
and is based primarily on evaluations of dichotomous
outcomes [12,14,15]. Therefore, empirical evidence on
the relationship between trial quality and treatment
effects may not be readily applicable to other health re-
search areas such as PT and other areas of rehabilitation.
Morever, information regarding the importance of in-
cluding certain items in quality tools within different
clinical areas is limited. As mentioned previously, RCTs
in the area of PT have distinct characteristics compared
with pharmacological trials conducted in medicine. PT
interventions are complex interventions [20]; they com-
prise certain characteristics such as the type of therapy
and its intensity, a standardized or individually tailored
approach, and the skills and experience of the therapists,
that are likely to affect trial results. In addition, because
of the nature of certain PT interventions (e.g., manual
therapy, exercises), blinding of therapists and/or patients
is not always possible. Appropriate blinding of study
participants and all key study personnel is unlikely to be
accomplished for most PT trials; however, blinding of
outcome assessment has been commonly used as aproxy quality measure without validation. Therefore,
more empirical evidence on trial bias is needed in the
area of PT to determine which factors are likely to affect
treatment effect estimates and thus provide accurate re-
sults for the clinical community. Further research should
examine the appropriateness of using certain items/
domains when evaluating the risk of bias of primary re-
search in a variety of health areas. This information
would provide clear benchmarks to assess the quality or
risk of bias of primary research included in SRs and
meta-analysis, and ultimately strengthen the evidence
for decision-making in all areas of health care.
The RoB tool is recommended by The Cochrane Col-
laboration. Some groups within the Collaboration have
developed their own tools and have not yet adopted the
RoB approach (e.g. Cochrane Bone, Joint and Muscle
Trauma Group). Other Cochrane groups have modified
the RoB tool for their own purposes (i.e. Cochrane Back
Review Group, Cochrane Renal Review Group). The
RoB tool was developed more recently than many of the
other tools; current research [9,13] recommends further
testing of its psychometric properties and validation of
the tool in a wide range of research fields. Additional
guidelines will help users in applying and interpreting
the results of the RoB tool.PT and general health research tool items and threats to
validity and precision
Most items from general health research and PT tools
were classified according to one or more categories of
threats to validity or precision; however, some items
could not be placed in any category. For example, the
item “study question/hypothesis/purpose described and
well defined” was not linked to any type of bias and was
found irrelevant for study quality. Nevertheless, this item
was included in 10 (53%) health research tools. This
situation raises concerns about the usefulness of certain
items to determine trial quality; therefore, these types of
items should be carefully considered when deciding
whether they should be part of these tools.
Classifying quality items was a complex task due to
unclear descriptions of the items and lack of empirical
evidence linking these items to bias. The number of
items that was linked to different types of bias varied by
tool. For example, a high percentage of items dealt with
selection bias (approximately 19% of general health and
21% of PT tools). In contrast, attrition bias was more
frequently represented in items found in PT (17%) com-
pared with general health research (7%) tools. These re-
sults call for an in-depth analysis of individual items of
tools that evaluate trial quality or risk of bias of RCTs in
health research in order to provide a more complete as-
sessment of their internal validity.
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The Jadad scale [37] is the most frequently cited tool in
health sciences research despite criticisms regarding its
lack of responsiveness [8] and applicability to other
health research areas such as PT and rehabilitation [5].
Herbison et al. [8], found that the Jadad scale might not
be responsive enough to distinguish among different
levels of trial quality. The use of the Jadad scale has been
discouraged in many areas of health research. The dis-
cordance between recommendations against using the
Jadad scale and its ongoing use is a matter of concern
and reasons for this discrepancy should be further ex-
plored. It is likely that the Jadad tool is popular among
SR authors because it is simple and requires little time
to apply [13].
None of the other quality tools used in general health
research and PT is as highly cited as the Jadad tool.
Some tools are specific to certain areas (e.g., PT, nursing,
psychology, pharmacology); most of them are long in-
struments and require a greater amount of time to
complete; and some lack clear guidelines for item assess-
ment, which can discourage their use.
Strengths and limitations
To the best of our knowledge, this study is the first to
exhaustively explore the type and frequency of individual
items included in tools that evaluate the quality or risk
of bias of RCTs in health research. A comprehensive
search was performed for all published research in this
area, with no language restrictions, and using several
strategies (i.e., manual search, Scopus) to identify rele-
vant literature. However, because of indexing problems
of research on the evaluation of quality assessment tools
for RCTs [19], some studies may have been missed; this
would not likely change our general findings.
Data extraction and item classification was performed
independently by two researchers with disagreements re-
solved by consensus. The process of classifying items
was somewhat subjective; therefore, classification of
some items may be debated. Difficulties in classifying
items as potentially linked to bias have been acknowl-
edged in previous studies that analyzed bias in different
types of research designs [25,28,65].
We used Scopus database to track all original papers
describing quality tools. We acknowledge that this ap-
proach is only an indirect measure of the usage of qual-
ity tools and should not be interpreted as absolute
indicator of usage over time.
Conclusion
There is a considerable number of tools to evaluate the
quality of RCTs in health research. There is extensive
variation in the number of individual items across qual-
ity assessment tools and an apparent lack of agreementbetween PT and general health research tools in the type
of items that are included. There is a need for clarity
and consistency of the constructs evaluated by items in
quality assessment tools, particularly for aspects related
to internal validity, external validity, precision, and qual-
ity of reporting. The selection of items to assess internal
validity, or risk of bias, should be based on empirical evi-
dence of an association with distortions of treatment ef-
fects. Finally, tools and items should undergo a thorough
validation process to examine their psychometric prop-
erties. Future studies in this area should investigate
which items are linked to bias through empirical evi-
dence or psychometric testing. This information will be
valuable for the field of knowledge synthesis.What is new?
Key findings
There is extensive item variation across tools that evalu-
ate the risk of bias of RCTs. There is a lack of empirical
evidence to support the association with bias for many
items.
What this adds to what is known: Although some
studies have previously addressed the use of tools for
quality assessment of RCTs, this is the first study that
exhaustively explores the type and frequency of items in-
cluded in different tools that evaluate the risk of bias of
RCTs in health research. The number of items included
across quality tools is large: 130 and 48 different items
have been used by general health research and physical
therapy (PT) tools, respectively. Many items are used
without a clear identification of their link to bias, or in-
ternal validity. The frequency of use of these items varies
according to health area (as demonstrated by our com-
parison between PT and general health research), which
suggests a lack of agreement regarding their relevance to
trial quality or risk of bias.
What is the implication, what should change now? Re-
sults of this study call for an in-depth empirical analysis
of the items that should be used to assess risk of bias of
RCTs in health research. This information is urgently
needed to develop guidelines for the design, conduct,
and implementation of trials. In addition, this informa-
tion is important for systematic reviewers and meta-
analysts to evaluate the risk of bias of intervention trials
in different areas of health research.Additional files
Additional file 1: Search Strategy Example.
Additional file 2: Definition of psychometric properties according
to Terwee et al., [24].
Additional file 3: Bias definitions.
Additional file 4: Excluded Studies.
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